// App-Quantinova.ai

SAT0398 : PERSISTENCE OF USTEKINUMAB (UST) OR TNF INHIBITOR (TNFI) TREATMENT IN PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE LARGE, PROSPECTIVE, MULTINATIONAL, REAL-WORLD PsABio COHORT

Researchers

Presenter

  • L. Gossec

Principal Investigators

  • S. Siebert

  • P. Bergmans

  • K. De Vlam

  • E. Gremese

  • B. Joven-Ibez

  • T. Korotaeva

  • W. Noel

  • M. T. Nurmohamed

  • P. Sfikakis

  • E. Theander

  • J. S. Smolen

Medical Centers

  • Sorbonne Universites, Paris, France

  • University of Glasgow, Glasgow, United Kingdom

  • Janssen, Breda, Netherlands

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Catholic University of the Sacred Heart, Fondazione Policlinico A Gemelli-IRCCS, Rome, Italy

  • Hospital Doce de Octubre, Madrid, Spain

  • Nasonova Research Institute of Rheumatology, Moscow, Russia

  • Janssen, Brussels, Belgium

  • VU University Medical Center, Amsterdam, Netherlands

  • University of Athens, Dental School, Athens, Greece

  • Janssen, Solna, Sweden

  • Medical University of Vienna, Vienna, Austria

Locations

  • France

  • United Kingdom

  • Netherlands

  • Belgium

  • Italy

  • Spain

  • Russia

  • Greece

  • Sweden

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Fibromyalgia

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • Tumor necrosis factor

  • Body mass index

Drug/Treatment

  • Glucocorticoid

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved